Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 398 publications over 31 distinct years, with a maximum of 30 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	1	1	2
1997	2	0	2
1998	2	0	2
1999	1	1	2
2000	0	2	2
2001	3	0	3
2002	5	3	8
2003	5	3	8
2004	5	7	12
2005	8	4	12
2006	4	5	9
2007	9	5	14
2008	10	7	17
2009	7	6	13
2010	7	6	13
2011	9	16	25
2012	10	9	19
2013	9	13	22
2014	19	8	27
2015	16	6	22
2016	8	13	21
2017	10	6	16
2018	13	9	22
2019	17	13	30
2020	11	10	21
2021	10	7	17
2022	0	6	6
2023	0	5	5
2024	6	4	10
2025	8	7	15

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Mateos MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester AK, Mayoh C, Holliday H, Liu J, Cui L, Pfaff E, Mackay A, Resnick AC, Pinese M, Lau LMS, Khuong-Quang DA, Dias K, Goudie C, Salkeld A, Rokita JL, Jones DTW, Juretic N, Hayden E, Pfister SM, Kramm CM, Blattner-Johnson M, Jabado N, Tsoli M, Vittorio O, Mueller S, Guo Y, Tucker K, Waszak SM, Perreault S, Jones C, Wong-Erasmus M, Cowley MJ, Ziegler DS. Germline analysis of an international cohort of pediatric diffuse midline glioma patients. Neuro Oncol. 2025 Sep 08; 27(7):1849-1863.

View in: PubMed
Van TTV, Tran TH, Nguyen THH, Nguyen VTC, Vo DH, Nguyen GTH, Nguyen TH, To KS, Nguyen AL, Tran CHA, Jasmine TX, Vo TL, Nai THT, Tran TT, Truong MH, Tran NC, Le TL, Nguyen THN, Tu NH, Tran TS, Le BT, Tang VP, Nguyen PTN, Nguyen KT, Ho VC, Nguyen XV, Doan NNT, Tran TT, Tran TMT, Tran VU, Le MP, Vu TL, Tieu BL, Nguyen HTP, Nguyen LHD, Phan NM, Van Phan T, Do TTT, Dao TH, Tang HS, Nguyen DS, Giang H, Phan MD, Nguyen HN, Vo DH, Tran LS. Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals. BMC Biol. 2025 Aug 20; 23(1):259.

View in: PubMed
Chung C, Lee KN, Shin DW, Lee SW, Han K. Serum ?-glutamyl transferase as a novel risk indicator for lung cancer: insights from four million Koreans. Respir Res. 2025 Jul 10; 26(1):242.

View in: PubMed
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, Hutchinson L, Li S, Xie Y, Selove W, Cerny J, Gerber JM. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer. 2025 Jul 01; 131(13):e35950.

View in: PubMed
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Pr?sper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20; 43(24):2739-2751.

View in: PubMed
Roy R, Schunkert EM, Olivova P, Gilar M, Geromanos S, Li GZ, Gebler J, Dagher A, El-Hayek A, Aldakhlallah R, Staffa SJ, Zurakowski D, Lotz M, Pories S, Moses MA. Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach. Breast Cancer Res. 2025 May 29; 27(1):94.

View in: PubMed
Freitas AJA, Causin RL, Calfa S, Santana IVV, Balie M, Hirai W, Laus AC, Araujo HS, Hidalgo Filho CM, de Oliveira Bombarda F, da Silva VD, Evangelista AF, de P?dua Souza C, Reis RM, Marques MMC. Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. Breast Cancer Res Treat. 2025 Jul; 212(2):237-250.

View in: PubMed
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB. CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival. J Mol Med (Berl). 2025 Jun; 103(6):725-737.

View in: PubMed
Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, Vesole DH, Nooka A, Paul B, Hari PN, D'Ambrosi S, Kuiper R, van Vliet M, Siegel D, Usmani SZ, van Rhee F. Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. Br J Haematol. 2025 Jun; 206(6):1642-1653.

View in: PubMed
Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.

View in: PubMed

People

Explore

Similar Concepts

Top Journals